Skip to main content
main-content

Expert opinion

From the Advisory Board

07-26-2017 | Non-small cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Here, Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

Author:
Fiona Blackhall

04-28-2017 | Genitourinary cancers | Editorial | Article

Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

Advisory Board member, Prof Axel Merseburger, discusses the key outcomes from the 2017 ASCO-GU Congress in Orlando, Florida.

Author:
Axel S Merseburger MD

03-14-2017 | Leukemia | Editorial | Article

FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

Advisory Board Member Xavier Thomas discusses the potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.

Author:
Xavier Thomas MD

01-26-2017 | Hematologic cancers | Editorial | Article

Immunotherapy comes of age in blood cancers

Advisory Board member Jasmine Zain discusses the development of various immunotherapy approaches and their potential clinical benefits for patients with blood cancers.

Author:
Jasmine Zain MD
image credits